Pluristem Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PSTI research report →
Price Chart
About the company
Pluristem Therapeutics Inc. , an Israeli biotechnology firm founded in 2001 and based in Haifa, specializes in the discovery, advancement, clinical assessment, and production of innovative cell-based therapeutic products. The company's primary focus is on addressing a spectrum of severe medical conditions, including those related to reduced blood flow (ischemia), inflammation, blood disorders, and autoimmune dysfunctions, using its proprietary technologies.
- CEO
- Yaky Yanay
- IPO
- 2007
- Employees
- 153
- HQ
- Haifa, IL
Get TickerSpark's AI analysis on PSTI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $40.85M
- P/E
- -0.60
- PEG
- 0.01
- P/S
- 34.88
- P/B
- -0.54
- EV/EBITDA
- -2.72
- Div Yield
- 0.00%
- Gross Margin
- 36.72%
- Op Margin
- -1908.63%
- Net Margin
- -870.11%
- ROE
- 79.27%
- ROIC
- 140.86%
Latest fiscal year · YoY change
- Revenue
- $1.34M+0.0%
- Gross Profit
- $654.00K+0.0%
- Op Income
- $-23,329,000
- Net Income
- $-23,250,000+0.0%
- EPS
- $-3.56+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- Beta
- 1.91
- RSI (14)
- 33
No earnings-call transcripts are available for PSTI yet.
- Free Float
- 76.6%
- Shares Outstanding
- 40.85M
- Float Shares
- 31.29M
of shares held by institutions
42 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Next Financial Group, Inc | 500 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 10, 22 | Aberman Zami | buy | 80,616 |
| May 26, 21 | CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | sell | 122,663 |
| May 26, 21 | CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | sell | 22,015 |
| May 27, 21 | CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | sell | 71,775 |
| May 27, 21 | CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | sell | 24,110 |
| May 28, 21 | CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | sell | 70,007 |
| May 28, 21 | CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | sell | 45,000 |
| May 21, 21 | CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | sell | 69,838 |
| May 24, 21 | CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | sell | 79,300 |
| May 25, 21 | CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | sell | 261,238 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PSTI coverage
Recent articles, reports, and earnings notes.
No research on PSTI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PSTI report →Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
zacks.com · Jul 14
Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery
benzinga.com · Jul 13
Best Penny Stocks to Buy as January Ends? 4 to Watch
pennystocks.com · Jan 22
Best Penny Stocks to Buy Right Now? 3 For Your List in January
pennystocks.com · Jan 10
Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform
benzinga.com · Jan 10
Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
zacks.com · Dec 28
Pluristem CEO Issues Shareholder Update
globenewswire.com · Sep 22
Pluristem Appoints Prof. Varda Shalev MD and Mr.
globenewswire.com · Jul 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.